Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: Down-regulation with essential fatty acids, ethanol and pentoxifylline

Medical Hypotheses

Volumn 52, Issue 5, 1999, Pages 465-477

  McCarty, M F ^a  

^a NutriGuard Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; C REACTIVE PROTEIN; ESSENTIAL FATTY ACID; FIBRINOGEN; FISH OIL; INTERLEUKIN 1; INTERLEUKIN 6; LINOLENIC ACID; PENTOXIFYLLINE; SEX HORMONE; TUMOR NECROSIS FACTOR;

ACUTE PHASE RESPONSE; ADIPOCYTE; ALCOHOL CONSUMPTION; BLOOD VISCOSITY; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; DIABETES MELLITUS; DOWN REGULATION; FIBRINOGEN BLOOD LEVEL; HYPERGLYCEMIA; LEUKOCYTOSIS; LUNG INJURY; OBESITY; PERIODONTAL DISEASE; PRIORITY JOURNAL; REVIEW; SMOKING; THROMBOEMBOLISM; THROMBOGENESIS;

THROMBUS;

EID: 0033037150     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1054/mehy.1997.0684     Document Type: Article

References (229)

1. Wilhelmsen L., Svärdsudd K., Korsan-Bengtsen K. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 311:1984;501-505.
2. Kannel W. B., Wolf P. A., Castelli W. P., D'Agostine R. B. Fibrinogen and risk of cardiovascullar disease. The Framingham Study. J Am Med Assoc. 258:1987;1183-1186.
3. Cook N. S., Ubben D. Fibrinogen as a major risk factor in cardiovascular disease. Trends Pharm Sci. 11:1990;444-451.
4. Yarnell J. W.G., Baker I. A., Sweetnam P. M. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell Collaborative Heart Disease Studies. Circulation. 83:1991;836-844.
5. Resch K. L., Ernst E., Matrai A., Paulsen H. F. Fibrinogen and viscosity as risk factors for subsequent cardiovascular events in stroke survivors. Ann Int Med. 117:1992;371-375.
6. Ernst E., Resch K. L. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med. 118:1993;956-963.
7. Thompson S. G., Kienast J., Pyke S. D.M. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 332:1995;635-641.
8. Dintenfass L. Elevation of blood viscosity, aggregation of red cells, haematocrit values and fibrinogen levels in cigarette smokers. Med J Aust. 1:1975;617-620.
9. Lowe D. G.D., Drummond M. M., Forbes C. D., Barbennel J. C. The effects of age and cigarette-smoking on blood and pIasma viscosity in men. Scot Med J. 25:1980;13-17.
10. Galea G., Davidson R. J.L. Haematological and haemorheological changes associated with cigarette smoking. J Clin Pathol. 38:1985;978-984.
11. Ernst E., Matrai A. Abstention from chronic cigarette smoking normalizes blood rheology. Atherosclerosis. 64:1987;75-77.
12. Kannel W. B., D'gostino R. B., Belanger A. J. Fibrinogen, cigarette smoking, and risk of cardiovascular disease: insights from the Framingham Study. Am Heart J. 113:1987;1006-1010.
13. Kannel W. B., McGee D. L., Castelli W. P. Latest perspectives on cigarette smoking and cardiovascular disease: The Framingham Study. J Cardiac Rehab. 4:1984;267-277.
14. Rosenberg L., Kaufman D. W., Helmrich S. P., Shapiro S. The risk of myocardial infarction after quitting smoking in men under 55 years of age. N Engl J Med. 313:1985;1511-1514.
15. Rosenberg L., Palmer J. R., Shapiro S. Decline in the risk of myocardial infarction among women who stop smoking. N Engl J Med. 322:1990;213-217.
16. Dormandy J. A., Reid H. L. Controlled defibrination in the treatment of peripheral vascular disease. Angiology. 29:1978;80-88.
17. Meade T. W., Vickers M. V., Thompson S. G., Seghatchian M. J. The effect of physiological1evels of fibrinogen on platelet aggregation. Thromb Res. 38:1985;527-534.
18. Corre F., Lellough J., Schwartz D. Smoking and leucocyte-counts. Lancet. ii:1971;632-634.
19. Zalokar J. B., Richard J. L., Claude J. R. Leukocyte count, smoking, and myocardial infarction. N Engl J Med. 304:1981;465-468.
20. Friedman G. D., Klatsky A. L., Siegelaub A. B. The leukocyte count as a predictor of myocardial infarction. N Engl J Med. 290:1974;1275-1278.
21. Grimm R. H., Neaton J. D., Ludwig W. Prognostic importance of the white cell count for coronary, cancer and all cause mortality. J Am Med Assoc. 254:1985;1932-1937.
22. Alderman M. J., Ridge A., Morely A. A. Effect of total leucocyte count on whole blood filterability in patients with peripheral vascular disease. J Clin Pathol. 34:1981;163-166.
23. Romson J. L., Hook B. G., Kunkel S. L. Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog. Circulation. 67:1983;1016-1023.
24. Ernst E., Hammerschmidt D. E., Bagge U. Leukocytes and the risk of ischemic diseases. J Am Med Assoc. 257:1987;2318-2324.
25. Schmid-Schönbein G. W. Capillary plugging by granulocytes and the no-reflow phenomenon in the microcirculation. Fed Proc. 46:1987;2397-2401.
26. Worthen G. S., Schwab B. III, Elson E. L., Downey G. P. Mechanics of stimulated neutrophils: cell stiffening induces retenhon in capillaries. Science. 245:1989;183-186.
27. Schmalzer E. A., Chien S. Filterability of subpopulations of leukocytes: effect of pentoxifylline. Blood. 64:1984;542-546.
28. Matrai A., Ernst E. Pentoxifylline improves white cell rheology in claudicants. Clin Hemorheol. 5:1985;483-491.
29. Hammerschmidt D. E., Kotasek D., McCarthy T. Pentoxifylline inhibits granulocyte and platelet function, including granulocyte priming by platelet activating factor. J Lab Clin Med. 112:1988;254-263.
30. Braquet P. Proofs of involvement of PAF-acether in various immune disorders using BN 52021 (ginkgolide B): a powerful PAF-acether antagonist isolated from ginkgo biloba L. Adv Prost Thromb Leuk Res. 16:1986;179-198.
31. Braquet P., Paubert-Braquet M., Koltai M. Is there a case for PAF antagonists in the treatment of ischemic states. Trends Pharm Sci. 10:1989;23-30.
32. Ridker P. M., Cushman M., Stampfer M. J. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 336:1997;973-979.
33. Cermak J., Key N. S., Bach R. R. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood. 82:1993;513-520.
34. Ernofsson M., Tenno T., Siegbahn A. Inhibition of tissue factor surface expression in human peripheral blood monocytes exposed to cytokines. Br J Haematol. 95:1996;249-257.
35. Nieminen M. S., Mattila K., Valtonen V. Infection and inflammation as risk factors for myocardial infarction. Eur Heart J. 14:1993;12-16.
36. Mattila K. J. Dental infections as a risk factor for acute myocardial infarction. Eur Heart J. 14:1993;51-53.
37. Kweider M., Lowe G. D., Murray G. D. Dental disease, fibrinogen and white cell count; links with myocardial infarction. Scot Med J. 38:1993;73-74.
38. Beck J., Garcia R., Heiss G. Periodontal disease and cardiovascular disease. J Periodontol. 67:1996;1123-1137.
39. Joshipura K. J., Rimm F. B., Douglass C. W. Poor oral health and coronary heart disease. J Dent Res. 75:1996;1631-1636.
40. Castell J. V., Góez-Lechón M. J., David M. Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett. 232:1988;347-350.
41. Castell J. V., Góez-Lechón M. J., David M. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett. 242:1989;237-239.
42. Castell J. V., Góez-Lechón M. J., David M. Acute-phase response of human hepatocytes: regulat1on of acute-phase protein synthesis by interleukin-6. Hepatology. 12:1990;1179-1186.
43. Heinrich P. C., Castell J. V., Andus T. Interleukin-6 and the acute phase response. Biochem J. 265:1990;621-636.
44. Hu C. H., Harris J. E., Davie E. W., Chung D. W. Characterization of the 5′-flanking region of the gene for the alpha chain of human fibrinogen. J Biol Chem. 270:1995;28342-28349.
45. Zhang Z., Fuentes N. L., Fuller G. M. Characterization of the IL-6 responsive elements in the gamma fibrinogen gene promoter. J Biol Chem. 270:1995;24287-24291.
46. Li S. P., Liu T. Y., Goldman N. D. Cis-acting elements responsible for interleukin-6 inducible C-reactive protein gene expression. J Biol Chem. 265:1990;4136-4142.
47. Li S. P., Goldman N. D. Regulation of human C-reactive protein gene expression by two synergistic IL-6 responsive elements. Biochemistry. 35:1996;9060-9068.
48. Zhang D., Sun M., Samols D., Kushner I. STAT3 participates in transcriptional activation of the C-reactive protein gene by interleukin-6. J Biol Chem. 271:1996;9503-9509.
49. Ganter U., Arcone R., Toniatti C. Dual control of C-reactive protein gene expression by interleukin-1 and interleukin-6. EMBO J. 8:1989;3773-3779.
50. Nijsten M. W., Hack C. E., Helle M. Interleukin-6 and its relation to the humoral immune response and clinical parameters in burned patients. Surgery. 109:1991;761-767.
51. Sheldon J., Riches P., Gooding R. C-reactive protein and its cytokine mediators in intensive-care patients. Clin Chem. 39:1993;147-150.
52. Gallo O., Gori A. M., Attanasio M. Interleukin-6 and acute-phase proteins in head and neck cancer. Eur Arch Otorhinolaryngol. 252:1995;159-162.
53. Lu Z. Y., Brailly H., Wijdenes J. Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments. Blood. 86:1995;3123-3131.
54. Banks R. E., Forbes M. A., Storr M. The acute phase protein response in patients receiving subcutaneous IL-6. Clin Exp Immunol. 102:1995;217-223.
55. Bataille R., Klein B. C-reactive protein levels as a direct indicator of interleukin-6 levels in humans invivo. Arthr Rheum. 35:1992;982-984.
56. Kowalski-Saunders P. W., Winwood P. J., Arthur M. J., Wright R. Reversible inhibition of albumin production by rat hepatocytes maintained on a laminin-rich gel (Engelbreth-Holm-Swarm) in response to secretory products of Kupffer cells and cytokines. Hepatology. 16:1992;733-741.
57. Phillips A., Shaper A. G., Winchup P. H. Association between serum albumin and mortality from cardiovascular disease, cancer, and other causes. Lancet. ii:1989;1434-1436.
58. Herrmann F. C., Safran C., Levkoff S. E., Minaker K. L. Serum albumin level on admission as a predictor of death, length of stay, and readmission. Arch Intern Med. 152:1992;125-130.
59. Kuller L. H., Eichner J. E., Orchard T. J. The relation between serum albumin levels and risk of coronary heart disease in the Multiple Risk Factor Intervention Trial. Am J Epidemiol. 134:1991;1266-1277.
60. Høstmark A. T. Serum fatty acid/albumin molar ratio and the risk of diseases. Med Hypotheses. 44:1995;539-551.
61. Björntorp P. 'Portal' adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis. 10:1990;493-496.
62. McCarty M. F. Reduction of free fatty acids may ameliorate risk factors associated with abdominal obesity. Med Hypotheses. 44:1995;278-286.
63. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes. 46:1997;3-10.
64. Halliwell B. Albumin - an important extracellular antioxidant. Biochem Pharm. 37:1988;569-571.
65. Folsom A. R., Wu K. K., Davis C. E. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis. 91:1991;191-205.
66. Krobot K., Hense H. W., Cremer P. Determinants of plasma fibrinogen: relation to body weight, waist-to-hip ratio, smoking, alcohol, age, and sex. Results from the second MONICA Augsburg Survey. Arterioscler Thromb. 12:1992;780-788.
67. Folsom A. R., Qamhieh H. T., Flack J. M. Plasma fibrinogen: levels and correlates in young adults. The Coronary Artery Risk Development in Young Adults (CARDIA) Study. Am J Epidemiol. 138:1993;1023-1036.
68. Iso H., Folsom A. R., Sato S. Plasma fibrinogen and its correlates in Japanese and US population samples. Arterioscler Thromb. 13:1993;783-790.
69. Licata G., Scaglione R., Avellone G. Hemostatic function in young subjects with central obesity: relationship with left ventricular function. Metabolism. 44:1995;1417-1421.
70. Avellone G., Di Garbo V., Cordova R. Coagulation, fibrinolysis and haemorheology in premenopausal obese women with different body fat distribution. Thromb Res. 75:1994;223-231.
71. Cigolini M., Targher G., Bergamo Andreis I. A. Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. Arterioscler Thromb Vasc Biol. 16:1996;368-374.
72. Targher G., Tonoli M., Agostino G. Ultrasonographic introabdominal depth and its relation to haemostatic factors in healthy males. Int J Obes. 20:1996;882-885.
73. Pickart L. R., Thaler M. M. Free fatty acids and albumin as mediators of thrombin-stimulated fibrinogen synthesis. Am J Physiol. 230:1976;996-1002.
74. Pickart L. Fat metabolism, the fibrinogen/fibrinolytic system and blood flow: new potentials for the pharmacgdogical treatment of coronary heart disease. Pharmacology. 23:1981;271-280.
75. Ernst E. Lowering the plasma fibrinogen concentration with drugs. Clin Pharmacol. 11:1992;968-971.
76. Mohamed-Ali V., Goodrick S., Rawesh A. Subcutaneous adipose tissue releases interleukin-6 but not tumour necrosis factor-α in vivo. Diabetes. 46:1997;55A.
77. Hotamisligil G. S., Shargill N. S., Spiegelman B. M. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science. 259:1993;87-91.
78. Hotamisligil G. S., Spiegelman B. M. Tumor necrosis factor a: a key component of the obesity-diabetes link. Diabetes. 43:1994;1271-1278.
79. Kern P. A., Saghizadeh M., Ong J. M. The expression of tumor necrosis factor in human adipose tissue. J Clin Invest. 95:1995;2111-2119.
80. Hotamisligil G. S., Arner P., Caro J. F. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest. 95:1995;2409-2415.
81. Doerrier W., Feingold K. R., Grunfeld C. Cytokines induce catabolic effects in cultured adipocytes by multiple mechanisms. Cytokine. 6:1994;478-484.
82. Green A., Dobias S. B., Walters D. J., Brasier A. R. Tumor necrosis factor increases the rate of lipolysis in primary cultures of adipocytes without altering levels of hormone-sensitive lipase. Endocrinology. 134:1994;2581-2585.
83. Skolnik E. Y., Marcusohn J. Inhibition of insulin receptor signaling by TNF: potential role in obesity and non-insulin-dependent diabetes mellitus. Cytokine Growth Factor Rev. 7:1996;161-173.
84. Long S. D., Pekala P. H. Lipid mediators of insulin resistance: ceramide signalling down-regulates GLUT4 gene transcription in 3T3-L1 adipocytes. Biochem J. 319:1996;179-184.
85. Stephens J. M., Lee J., Pilch P. F. Tumor necrosis factor-alpha-induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal transduction. J Biol Chem. 272:1997;971-976.
86. Grunfeld C., Zhao C., Fuller J. Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. J Clin Invest. 97:1996;2151-2157.
87. Sarraf P., Frederich R. C., Turner E. M. Multiple cytokines and acute inflammation raise mouse leptin levels: potential role in inflammatory anorexia. J Exp Med. 185:l997;171-175.
88. Schwartz M. W., Baskin D. G., Bukowski T. R. Specificity of leptin action on elevated blood glucose levels and hypothalamic neuropeptide Y gene expression in ob/ob mice. Diabetes. 45:1996;531-535.
89. Legradi G., Emerson C. H., Ahima R. S. Leptin prevents fasting-induced suppression of prothyrotropin-releasing hormone messenger ribonucleic acid in neurons of the hypothalamic paraventricular nucleus. Endocrinology. 138:1997;2569-2576.
90. Schwartz M. W., Seeley R. J. The new biology of weight reduction. J Am Diet Assoc. 97:1997;54-58.
91. Fraze E., Donner C. C., Swislicki A. L.M. Ambient plasma free fatty acid concentrations in noninsulin-dependent diabetes mellitus: evidence for insulin resistance. J Clin Endocrinol Metab. 61:1985;807-811.
92. Cerami A., Buetler B. The role of cachectin/TNF in endotoxic shock and cachexia. Immunol Today. 9:1988;28-31.
93. Kern K. A., Norton J. A. Cancer cachexia. J Parent Enter Nutr. 12:1988;286-298.
94. Berg M., Fraker D. L., Alexander H. R. Characterization of differentiation factor/leukaemia inhibitory factor effect on lipoprotein lipase activity and mRNA in 3T3-L1 adipocytes. Cytokine. 6:1994;425-432.
95. Muller G., Ertl J., Gerl M., Preibisch G. Leptin impairs metabolic actions in isolated rat adipocytes. J Biol Chem. 272:1997;10585-10593.
96. Greenberg A. S., Nordan R. P., McIntosh J. Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: a possible role for interleukin 6 in cancer cachexia. Cancer Res. 52:1992;4113-4116.
97. Schultz F. H., Knobloch H. Über das Fibrinogen beim Diabetes mellitus. Dtsch Z Verd Stoffnechsel. 15:1955;218-222.
98. Paisey R. B., Harkness J., Hartog M., Chadwick T. The effect of improvement in diabetic control on plasma and whole blood viscosity. Diabetologia. 19:1980;345-349.
99. Shihabi Z. K., Konen J. C., McCormick C. P. Plasma fibrinogen levels in type II diahetes. Clin Physiol Biochem. 8:1990;297-300.
100. Kato H., Morohoshi M., Uchimura I., Numano F. Glucose increases endothelial interleukin 6 production suppressed by adequate shear stress. Diabetes. 46:1997;112A.
101. 2-interferon/B-cell differentiation factor BSF-2 gene expression in human fibroblasts by diacylglycerols and the calcium ionophore A23187. Proc Natl Acad Sci. 84:1987;3663-3667.
102. 2-interferon/hepatocyte-stimulating factor/interleukin 6' promoter by cytokines, viruses, and second messenger agonists. Proc Natl Acad Sci. 85:1988;6701-6705.
103. Inoguchi T., Battan R., Handler E. Preferential elevation of protein kinase C isoform βII and diacylglycerol levels in the aorta and heart of diabetic rats: difirerential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci. 89:1992;11059-11063.
104. Ishii H., Jirousek M. R., Kova D. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor. Science. 272:1996;728-731.
105. Primrose J. N., Davies J. A., Prentice C. R. Reduction in factor VII, fibrinogen and plasminogen activator inhibitor-1 activity after surgical treatment of morbid obesity. Thromb Haemost. 68:1992;396-399.
106. Ernst E. Does weight loss reduce plasma fibrinogen. Br Heart J. 70:1993;116-118.
107. Ditschuneit H. H., Flechtner-Mors M., Adler G. Fibrinogen in obesity before and after weight reduction. Obesity Res. 3:1995;43-48.
108. Stratton J. R., Chandler W. L., Schwartz R. S. Effects of physical conditioning on fibrinolytic variables and fibrinogen in young and old healthy adults. Circulation. 83:1991;1692-1697.
109. Connelly J. B., Cooper J. A., Meade T. W. Strenuous exercise, plasma fibrinogen, and factor VII activity. Br Heart J. 67:1992;351-354.
110. Elwood P. C., Yarnell J. W.G., Pickering J. Exercise, fibrinogen, and other risk factors for ischaemic heart disease. Caerphilly prospective heart disease study. Br Heart J. 69:1993;183-187.
111. Deprés J.-P., Tremblay A., Nadeau A., Bouchard C. Physical training and changes in regional adipose tissue distribution. Acta Med Scand. 723:1988;205-212.
112. Ross R., Rissanen J. Mobilization of visceral and subcutaneous adipose tissue in response to energy restriction and exercise. Am J Clin Nutr. 60:1994;695-703.
113. Buemann B., Tremblay A. Effects of exercise training on abdominal obesity and related metabolic complications. Sports Med. 21:1996;191-212.
114. Sato S., Iso H., Naito Y. Plasma fibrinogen and its correlates in urban Japanese men. Int J Epidemiol. 25:1996;521-527.
115. Høstmark A. T., Bjerkedal T., Kierulf P. Fish oil and plasma fibrinogen. Br Med J. 297:1988;180-181.
116. Radack K., Deck C., Huster G. Dietary supplementation with low-dose fish oils lowers fibrinogen levels: a randomized, double-blind controlled study. Ann Intern Med. 111:1989;757-758.
117. Haglund O., Wallin R., Luostarinen R., Saldeen T. Effects of a new fluid fish oil concentrate, ESKIMO-3, on triglycerides, cholesterol, fibrinogen and blood pressure. J Intern Med. 227:1990;347-353.
118. Saynor R., Gillott T. Changes in blood lipids and fibrinogen with a note on safety in a long term study on the effects of n-3 fatty acids in subjects receiving fish oil supplements and followed for seven years. Lipids. 27:1992;533-538.
119. Wigmore S. J., Ross J. A., Falconer J. S. The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition. 12:1996;S27-S30.
120. Wigmore S. J., Fearon K. C.H., Maingay J. P., Ross J. A. Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6. Clin Sci. 92:1997;215-221.
121. Endres S., Ghorbani R., Kelley V. E. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-l and tumor necrosis factor by mononuclear cells. N Engl J Med. 320:1989;265-271.
122. Meydani S. N., Endres S., Woods M. M. Oral (n-3) fatty acid supplementation suppresses cytokine production and lymphocyte proliferation: comparison between young and older women. J Nutr. 121:1991;547-555.
123. Gallai V., Sarchielli P., Trequattrini A. Cytokine secretion and eicosanoid production in the peripheral blood mononuclear cells of MS patients undergoing dietary supplementation with n-3 polyunsaturated fatty acids. J Neuroimmunol. 56:1995;143-153.
124. Endres S. n-3 polyunsaturated fatty acids and human cytokine synthesis. Lipids. 31:1996;S239-S242.
125. Blok W. L., Katan M. B., van der Meer J. W.M. Modulation of inflammation and cytokine production by dietary (n-3) fatty acids. J Nutr. 126:1996;1515-1533.
126. Dinarello C. A., Bishai I., Rosenwasser L. J., Coceani F. The influence of lipoxygenase inhibitors on the in vitro production of human leukocytic pyrogen and lymphocyte activating factor (interleukin 1). Int J Immunopharmacol. 6:1984;43-50.
127. Kunkel S. L., Chensue S. W. Arachidonic acid metabolites regulate interleukin 1 production. Biochem Biophvs Res Comm. 128:1985;892-897.
128. Rola-Pleszcsynski M., Lemaire I. Leukotriences augment interleukin 1 production by human monocytes. J Immunol. 135:1985;3958-3961.
129. Lee T. H., Hoover R. L., Williams J. D. Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. N Engl J Med. 312:1985;1217-1224.
130. Sperling R. I. Effects of dietary fish oil on leukocyte leukotriene and PAF generation and on neutrophil chemotaxis. Simopoulos A. P., Kifer R. R., Martin R. E., Barlow S. M. Health Effects of ω3 Polyunsaturated Fatty Acids in Seafoods. 1991;391-400 Karger, Basel.
131. Caughey G. E., Mantzioris E., Gibson R. A. The effect on human tumor necrosis factor α and interleukin 1β production of diets enriched in n-3 fatty acids from vegetable oil or fish oil. Am J Clin Nutr. 63:1996;116-122.
132. 4. Am J Clin Nutr. 55:1992;39-45.
133. Vanderhoek J. Y., Bryant R. W., Bailey J. M. Regulation of leukocyte and platelet lipoxygenases by hydroxyeicosanoids. Biochem Pharm. 31:1982;3463-3467.
134. Miller C. C., Tang W., Ziboh V. A., Fletcher M. P. Dietary supplementation with ethyl ester concentrates of fish oil (n-3) and borage oil (n-6) polyunsaturated fatty acids induces epidermal generation of local putative antiinflammatory metabolites. J Invest Dermatol. 96:1991;98-103.
135. Watson J., Byars M. L., McGill P., Kelman A. W. Cytokine and prostaglandin production by monocytes of volunteers and rheumatoid arthritis patients treated with dietary supplements of blackcurrant seed oil. Br J Rheumatol. 32:1993;1055-1058.
136. Purasiri P., Murray A., Richardson S. Modulation of cytokine production in vivo by dietary essential fatty acids in patients with colorectal cancer. Clin Sci. 87:1994;711-717.
137. Leventhal L. J., Boyce E. G., Zurier R. B. Treatment of rheumatoid arthritis with gammalinolenic acid. Ann Intern Med. 119:1993;867-873.
138. Ward A., Clissold S. P. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs. 34:1987;50-97.
139. Strieter R. M., Remick D. G., Ward P. A. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Comm. 155:1988;1230-1236.
140. Doherty G. M., Jensen J. C., Alexander H. R. Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery. 110:1991;192-198.
141. Bernard C., Barnier P., Merval R. Pentoxifylline selectivity inhibits tumor necrosis factor synthesis in the arterial wall. J Cardiovasc Pharm. 25:1995;30-33.
142. Jarrett P. E.M., Moreland M., Browse N. L. The effect of pentoxifylline ('Trental') on fibrinogen activity and plasma fibrinogen levels. Curr Med Res Opin. 4:1977;492-495.
143. Solerte S. B., Ferrari E. Diabetic retinal vascular complications and erythrocyte filtrability; results of a 2-year follow-up study with pentoxifylline. Pharmatherapeutica. 4:1985;341-350.
144. Perego M. A., Sergio G., Artale F. Haemorrheological improvement by pentoxifylline in patients with peripheral arterial occlusive disease. Curr Med Res Opin. 10:1986;135-138.
145. Ferrari E., Fioravanti M., Patti A. L. Effects of long-term treatment (4 years) with pentoxifylline on haemorrheological changes and vascular complications in diabetic patients. Pharmatherapeutica. 5:1987;26-39.
146. Deutschinoff A., Grozdinsky L. Rheological and anticoagulant therapy of patients with chronic peripheral occlusive arterial disease (COAD). Angiology. 38:1987;351-357.
147. Soria J., Lancrenon S., Chassoux G. Fibrinogen and pentoxifylline. Results of a French cooperative exploratory study of stage II arteritis. J Mal Vasc. 14:1989;29-34.
148. Bachet P., Lancrenon S., Chassoux G. Fibrinogen and pentoxifylline. Thromb Res. 55:1989;161-163.
149. Herskovits E., Famulari A., Tamaroff L. Randomized trial of pentoxifylline versus acetylsalicylic acid plus dipyridamole in preventing transient ischemic attacks. Lancet. i:1981;966-968.
150. Herskovits E., Famulari A., Tamaroff L. Preventive treatment of cerebral transient ischemia: comparative randomized trial of pentoxifylline versus conventional antiaggregants. Eur Neurol. 24:1985;73-81.
151. Ott E., Körner E., Lechner H. Hemorheologic treatment of cerebral reversible ischemic episodes with pentoxifylline - a prospective study. Angiology. 39:1988;520-525.
152. Herskovits E., Famulari A., Tamarof L. Comparative study of pentoxifylline vs antiaggregants in patients with transient ischaemic attacks. Acta Neurol Scand. 127:1989;31-35.
153. Apollonia A., Castignani P., Magrini L., Angeletti R. Ticlopidine-pentoxifylline combination in the treatment of atherosclerosis and the prevention of cerebrovascular accidents. J Int Med Res. 17:1989;28-35.
154. Raptis S., Mitrakou A., Hadjidakis D. 24-h blood glucose pattern in type I and type II diabetics after oral treatment with pentoxifylline as assessed by artificial endocrine pancreas. Acta Diabetol Lat. 24:1987;181-192.
155. Nilsson N. O., Belfrage P. Effects of acetate, acetaldehyde, and ethanol on lipolysis in isolated rat adipocytes. J Lipid Res. 19:1978;737-741.
156. Larsen T. S., Nilsson N. O., Blix A. S. Effects of volatile fatty acids and ketone bodies on lipolysis in isolated adipocytes from Norwegian reindeer (Rangifer tarandus). Acta Physiol Scand. 117:1983;451-455.
157. Akanji A. O., Bruce M. A., Frayn K. N. Effect of acetate infusion on energy expenditure and substrate oxidation rates in non-diabetic and diabetic subjects. Eur J Clin Nutr. 43:1989;107-115.
158. Suokas A., Kupari M., Heikkilä J. Acute cardiovascular and metabolic effects of acetate in men. Alcohol Clin Exp Res. 12:1988;52-58.
159. Avogaro A., Beltramello P., Gnudi L. Alcohol intake impairs glucose counterregulation during acute insulin-induced hypoglycemia in IDDM patients. Evidence for a critical role of free fatty acids. Diabetes. 42:1993;1626-1634.
160. Christiansen C., Thomsen C., Rasmussen O. The acute impact of ethanol on glucose, insulin, triacylglycerol, and free fatty acid responses and insulin sensitivity in type 2 diabetes. Br J Nutr. 76:1996;669-675.
161. Facchini F., Chen Y.-D. I., Reaven G. M. Light-to-moderate alcohol intake is associated with enhanced insulin sensitivity. Diabetes Care. 17:1994;115-119.
162. Kiechl S., Willeit J., Poewe W. Insulin sensitivity and regular alcohol consumption: large, prospective, cross sectional population study (Bruneck study). Br Med J. 313:1996;1040-1044.
163. Lazarus R., Sparrow D., Weiss S. T. Alcohol intake and insulin levels. The normative aging study. Am J Epidemiol. 145:1997;909-916.
164. Rimm E. B., Chan J., Stampfer M. J. Prospective study of cigarette smoking, alcohol use, and the risk of diabetes in men. Br Med J. 310:1995;555-559.
165. Koepp P., Hegewisch S. Effects of guar on plasma viscosity and related parameters in diabetic children. Eur J Pediatr. 137:1981;31-33.
166. Venter C. S., Vorster H. H. Possible metabolic consequences of fermentation in the colon for humans. Med Hypotheses. 29:1989;161-166.
167. Tuma D. J., Todero S. L., Barak-Bernhagen M., Sorrell M. F. Effects of chronic ethanol adminlstration on the endocytosis of cytokines by rat hepatocytes. Alcohol Clin Exp Res. 20:1996;579-583.
168. Deaciuc I. V., Alappat J. M., McDonough K. H., D'Souza N. B. Effect of chronic alcohol consumption by rats on tumor necrosis factor-α and interleukin-6 clearance in vivo and by the isolated, perfused liver. Biochem Pharm. 52:1996;891-899.
169. Nadkarni G. D., Pestonjamasp K. N. Effect of ethanol on turpentine-induced acute phase response in rats. Biochem Pharm. 34:1985;525-527.
170. Worrall S., Wilce P. A. The effect of chronic ethanol feeding on cytokines in a rat model of alcoholic liver disease. Alcohol Alcohol. 2:1994;447-451.
171. Lands W. E.M., Zakhari S. The case of the missing calories. Am J Clin Nutr. 54:1991;47-48.
172. Lieber C. S. Perspectives: do alcohol calories count. Am J Clin Nutr. 54:1991;976-982.
173. Suter P. M., Schutz Y., Jequier E. The effect of ethanol on fat storage in healthy subjects. N Engl J Med. 326:1992;983-987.
174. Holbrook T. L., Barrett-Connor E. A prospective study of alcohol consumption and bone mineral density. Br Med J. 306:1993;1506-1509.
175. Jilka R. L., Hangoc G., Girasole G. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science. 257:1992;88-91.
176. Hughes F. J., Howells G. L. Interleukin-6 inhibits bone formation in vitro. Bone Min. 21:1993;21-28.
177. Sakaguchi K., Morita I., Murota S. Eicosapentaenoic acid inhibits bone loss due to ovariectomy in rats. Prostaglandins Leukot Essent Fatty Acids. 50:1994;81-84.
178. Robin J. C., Ambrus J. L. Studies on osteoporoses. XI Effects of a methylxanthine derivative. J Med. 14:1983;137-145.
179. Wakley G. K., Schutte H. D. Jr, Hannon S. K., Turner R. T. Androgen treatment prevents loss of cancellous bone in the orchidectomized rat. J Bone Miner Res. 6:1991;325-330.
180. Poli V. R., Balena E., Fattori A. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletoin. EMBO J. 13:1994;1189-1196.
181. Ray A., Prefontaine K. E ., Ray P. Down-modulation of interleukin-6 gene expression by 17 beta-estradiol in the absence of high affinity DNA binding by the estrogen receptor. J Biol Chem. 269:1994;12940-12946.
182. Stein B., Yang M. X. Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-κB and C/EBPβ Mol Cell Biol. 15:1995;4971-4979.
183. Bellido T., Jilka R. L., Boyce B. F. Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. J Clin Invest. 95:1995;2886-2895.
184. Bismar H., Diel I., Ziegler R., Pfeilschifter J. Increased cytokine secretion by human bone marrow cells after menopause or discontinuation of estrogen replacement. J Bone Miner Res. 9:1994;158.
185. Kassem M., Khosla S., Spelsberg T. C., Riggs B. L. Cytokine production in the bone marrow microenvironment: failure to demonstrate estrogen regulation in early postmenopausal women. J Clin Endocrinol Metab. 81:1996;513-518.
186. Cantatore F. P., Loverro G., Ingrosso A. M. Effect of oestrogen replacement on bone metabolism and cytokines in surgical menopause. Clin Rheum. 14:1995;157-160.
187. J Am Med Assoc. 273:1995;199-208.
188. Gebara O. C.E., Mittleman M. A., Sutherland P. Association between increased oestrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation. 91:1995;1952-1958.
189. Thromb Haem. 75:1996;476-480.
190. Meilahn E. N., Cauley J. A., Tracy R. P. Association of sex hormones and adiposity with plasma levels of fibrinogen and PAI-1 in postmenopausal women. Am J Epidemiol. 143:1996;159-166.
191. Bush T. L. Evidence for prirnary and secondary prevention of coronary artery disease in women taking oestrogen replacement therapy. Eur Heart J. 17:1996;9-14.
192. Rosano G. M.C., Chierchia S. L., Leonardo F. Cardioprotective effects of ovarian hormones. Eur Heart J. 17:1996;15-19.
193. Draper M. W., Flowers D. E., Huster W. J. A controlled trial of Raloxifene (LY 139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res. 11:1996;835-842.
194. Finkelstein J. S., Klibanski A., Neer R. M. Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 69:1989;776-783.
195. Katznelson L., Finkelstein J. S., Schoenfeld D. A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab. 81:1996;4358-4365.
196. Mrin P., Holmäng S., Gustafsson C. Androgen treatment of abdominally obese men. Obesity Res. 1:1993;245-251.
197. Mårin P. Testosterone and regional fat distribution. Obesity Res. 3:1995;609-612.
198. Haarbo J., Marslew U., Gottfredsen A., Christiansen C. Postmenopausal hormone replacement therapy prevents central distribution of body fat after menopause. Metabolism. 40:1991;323-326.
199. Pacifici R., Rifas L., McCracken R. Ovarian steroid treatment blocks a postmenopausal increase in blood monocyte interleukin 1 release. Proc Natl Acad Sci. 86:1989;2398-2402.
200. Kimble R. B., Vannice J. L., Bloedow D. C. Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats. J Clin Invest. 93:1994;1959-1967.
201. Kitasawa R., Kimble R. B., Vannice J. L. Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice. J Clin Invest. 94:1994;2397-2406.
202. Terano T., Hirai H., Hamazaki T. Effect of oral administration of highly purified eicosapentaenoic acid on platelet function, blood viscosity and red cell deformability in healthy human subjects. Atherosclerosis. 46:1983;321-331.
203. Cartwright I. J., Pockley A. G., Galloway J. H. The effects of dietary ω-3 polyunsaturated fatty acids on erythrocyte membrane phospholipids, erythrocyte deformability and blood viscosity in healthy volunteers. Atherosclerosis. 55:1985;267-281.
204. Mills D. E., Galey W. F., Dixon H. Effects of dietary fatty-acid supplementation on fatty-acid composition and deformability of young and old erythrocytes. Biochim Biophys Acta. 1149:1993;313-318.
205. Sanders T. A.B., Vickers M., Haines A. P. Effect on blood lipids and haemostasis of a supplement of cod-liver oil, rich in eicosapentaenoic and docosahexaenoic acids, in healthy young men. Clin Sci. 61:1981;317-324.
206. Lorenz R., Spengler U., Fischer S. Platelet function, thromboxane formation and blood pressure control during supplementation of the western diet with cod liver oil. Circulation. 67:1983;504-511.
207. Saynor R., Verel D., Gillott T. The long-term effect of dietary supplementation with fish lipid concentrate on serum lipids, bleeding time, platelets and angina. Atherosclerosis. 50:1984;3-10.
208. Kristensen S. D., Schmidt E. B., Dyerberg J. Dietary supplementation with n-3 polyunsaturated fatty acids and human platelet function: a review with particular emphasis on implications for cardiovascular disease. J Intern Med. 225:1989;141-150.
209. Barcelli U., Glas-Greenwalt P., Pollak V. E. Enhancing effect of dietary supplementation with ω-3 fatty acids on plasma fibrinolysis in normal subjects. Thromb Res. 39:1985;307-312.
210. Shimokawa H., Lam J. Y.T., Chesebro J. H. Effects of dietary supplementation w1th cod-liver oil on endothelium-dependent responses in porcine coronary arteries. Circulation. 76:1987;898-905.
211. Boulanger C., Schini V. B., Hendrickson H., Vanhoutte P. M. Chronic exposure of cultured endothelial cells to eicosapentaenoic acid potentiates the release of endothelium-derived relaxing factor(s). Br J Pharmacol. 99:1990;176-180.
212. Renier G., Skamene E., DeSanctis J., Radzioch D. Dietary n-3 polyunsaturated fatty acids prevent the development of atherosclerotic lesions in mice. Modulation of macrophage secretory activities. Arterioscler Thromb. 13:1993;1515-1524.
213. McLennan P. L., Abeywardena M. Y., Charnock J S. Dietary fish oil prevents ventricular fibrillation following coronary artery occlusion and reperfusion. Am Heart J. 116:1988;709-717.
214. Riemersma R. A., Sargent C. A. Dietary fish oil and ischaemic arrhythmias. J Intern Med. 225:1989;111-116.
215. McLennan P. L. Relative effects of dietary saturated, monounsaturated, and polyunsaturated fatty acids on cardiac arrhythmias in rats. Am J Clin Nutr. 57:1993;207-212.
216. Gapinski J. P., VanRuiswyk J. V., Heudebert G. R., Schectman G. S. Preventing restenosis with fish oils following coronary angioplasty. A meta-analysis. Arch Intern Med. 153:1993;1595-1601.
217. Gorinstein S., Zemser M., Lichman I. Moderate beer consumption and the blood coagulation in patients with coronary artery disease. J Int Med. 241:1997;47-51.
218. Suh I., Shaten J., Cutler J. A., Kuller L. H. Alcohol use and mortality from coronary heart disease: the role of high-density lipoprotein cholesterol. Ann Int Med. 116:1992;881-887.
219. Nawroth P. P., Handley D. A., Esmon C. T., Stern D. M. Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity. Proc Natl Acad Sci. 83:1986;3460-3464.
220. Bevilacqua M. P., Pober J. S., Majeau G. R. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci. 83:1986;4533-4537.
221. Kobayashi M., Shimada K., Ozawa T. Human recombinant interleukin-1 beta- and tumor necrosis factor alpha-mediated suppression of heparin-like compounds on cultured porcine aortic endothelial cells. J Cell Physiol. 144:1990;383-390.
222. Robson S. C., Kaczmarek E., Siegel J. B. Loss of ATP diphosphohydrolase activity with endothelial cell activation. J Exp Med. 185:1997;153-163.
223. Hajjar K. A., Hajjar D. P., Silverstein R. L., Nachman R. L. Tumor necrosis factor-mediated release of platelet-derived growth factor from cultured endothelial cells. J Exp Med. 166:1987;235-245.
224. Raines E. W., Dower S. K., Ross R. Interleukin-1 mitogenic activity for fibroblasts and smooth muscle cells is due to PDGH-AA. Science. 243:1989;393-396.
225. Yoshizumi M., Perrella M. A., Burnett J. C. Jr, Lee M.-E. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res. 73:1993;205-209.
226. Morimoto M., Zern M. A., Hagbjörk A.-L. Fish oil, alcohol, and liver pathology: role of cytochrome P450 2E1. Proc Soc Exp Bio Med. 207:1994;197-205.
227. Harats D., Dabach Y., Hollander G. Fish oil ingestion in smokers and nonsmokers enhances peroxidation of plasma lipoproteins. Atherosclerosis. 90:1991;127-139.
228. Malhotra S. L. Studies in blood coagulation, diet, and ischaemic heart disease in two population groups in India. Br Heart J. 30:1968;303-308.
229. McCarty M. F. Promotion of hepatic lipid oxidation and gluconeogenesis as a strategy for appetite control. Med Hypotheses. 42:1994;215-225.